Zimmer Biomet Holdings, Inc. (ZBH)
|52 Week Range||100.39-149.25|
|1y Target Est||-|
|DCF Unlevered||ZBH DCF ->|
|DCF Levered||ZBH LDCF ->|
|Debt / Equity||74.73%||Buy|
Upgrades & Downgrades
Latest ZBH news
Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)
30 May 2023
Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
29 May 2023
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and ResMed (RMD). But which of these two stocks offers value investors a better ban...
Here's Why Investors Should Add Zimmer Biomet (ZBH) Now
23 May 2023
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
3 Stocks That Are Reshaping the Future
16 May 2023
Investors can find growth plays in many corners of the stock market, but a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend ...
What Makes Zimmer Biomet (ZBH) a Strong Momentum Stock: Buy Now?
3 May 2023
Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised
2 May 2023
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
2 May 2023
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.89 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.61 per share a year ago.
ZBH or LMAT: Which Is the Better Value Stock Right Now?
26 April 2023
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better ban...
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
25 April 2023
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >